JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 28, 2006; DOI: 10.1124/jpet.106.106500


0022-3565/06/3191-20-30$20.00
JPET 319:20-30, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.106.106500v1
319/1/20    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tough, I. R.
Right arrow Articles by Cox, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tough, I. R.
Right arrow Articles by Cox, H. M.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Y4 Receptors Mediate the Inhibitory Responses of Pancreatic Polypeptide in Human and Mouse Colon MucosaFormula

Iain R. Tough, Nicholas D. Holliday, and Helen M. Cox

Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom

The antisecretory effects of several Y agonists, including pancreatic polypeptide (PP), indicate the presence of Y1, Y2, and Y4 receptors in mouse and human (h) colon mucosae. Here, we used preparations from human and from wild-type (WT), Y4, and Y1 receptor knockout (-/-) mice, alongside Y4 receptor-transfected cells to define the relative functional contribution of the Y4 receptor. First, rat (r) PP antisecretory responses were lost in murine Y4-/- preparations, but hPP and Pro34 peptide YY (PYY) costimulated Y4 and Y1 receptors in WT mucosa. The Y1 antagonist/Y4 agonist GR231118 [(Ile,Glu,Pro,Dpr,Tyr,Arg,Leu,Arg,Try-NH2)-2-cyclic(2,4'),(2',4)-diamide] elicited small Y4-mediated antisecretory responses in human tissues pretreated with the Y1 antagonist, BIBO3304 [(R)-N-[[4-(aminocarbonylaminomethyl)-phenyl]methyl]-N2-(diphenylacetyl)-argininamide trifluoroacetate)], and attenuated Y4-mediated hPP responses in mouse and human mucosa. GR231118 and rPP were also antisecretory in hY4-transfected epithelial monolayers but were partial agonists compared with hPP at this receptor. In Y4-transfected human embryonic kidney (HEK) 293 cells, Y4 ligands displaced [125I]hPP binding with orders of affinity (pKi) at human (hPP = rPP > GR231118 > Pro34PYY = PYY) and mouse (rPP = hPP > GR231118 > Pro34PYY > PYY) Y4 receptors. GR231118- and rPP-stimulated guanosine 5'-3-O-(thio)triphosphate binding through hY4 receptors with significantly lower efficacy than hPP. GR231118 marginally increased basal but abolished further PP-induced hY4 internalization to recycling (transferrin-labeled) pathways in HEK293 cells. Taken together, these findings show that Y4 receptors play a definitive role in attenuating colonic anion transport and may be useful targets for novel antidiarrheal agents due to their limited peripheral expression.


Received April 19, 2006; accepted June 27, 2006.

Address correspondence to: Dr. Helen M. Cox, Wolfson Centre for Age-Related Diseases, King's College London, Guy's Campus, London SE1 1UL, UK. E-mail: helen.m.cox{at}kcl.ac.uk







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.